Ajanta Pharma USA Inc. C/O Rxcrossr Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Ajanta Pharma USA Inc. C/O Rxcrossr Pharmaceutical Import Records from India — 3 Products, $3.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ajanta Pharma USA Inc. C/O Rxcrossr — Pharmaceutical Importer Profile (2026) | 3 Products, $3.4M Trade | TransData Nexus

Ajanta Pharma USA Inc. C/O Rxcrossr

Pharmaceutical Importer · United States · Lipid & Metabolism Focus · $3.4M Total Trade · DGFT Verified

Ajanta Pharma USA Inc. C/O Rxcrossr is a pharmaceutical importer based in United States with a total trade value of $3.4M across 3 products in 3 therapeutic categories. Based on 112 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Ajanta Pharma USA Inc. C/O Rxcrossr sources from 1 verified Indian supplier, with Ajanta Pharma Limited accounting for 100.0% of imports.

Ajanta Pharma USA Inc. C/O Rxcrossr — Import Portfolio & Supplier Network

Ajanta Pharma USA Inc. C/O Rxcrossr import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Ajanta Pharma USA Inc. C/O Rxcrossr?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Ajanta Pharma Limited	$3.6M	205	100.0%

Ajanta Pharma USA Inc. C/O Rxcrossr sources from 1 verified Indian supplier across 146 distinct formulations. The sourcing is highly concentrated — Ajanta Pharma Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Duloxetine delayed release capsules 30MG	$200.0K	4
Duloxetine delayed release capsules 20MG	$188.8K	4
Duloxetine delayed release capsules 60MG	$150.0K	3
Oxybutynin chloride extended-release TAB	$150.0K	8
Amlodipine 5MG and olmesartan	$85.3K	4
Amlodipine 10MG and olmesartan	$63.8K	6
Duloxetine delayed release capsules 40MG	$62.4K	4
Sildenafil tablets 20MG 147348pacx1x90 13261320tab Each film coated TAB cont sildenafil citrate USP eq to sildenafil	$50.0K	1
Fenofibrate tablets USP 160MG 34344pacx1x90 3090960 tablets Each film coated tabelt contains fenofibrate USP 160MG	$50.0K	1
Duloxetine delayed release capsules 60MG 319584pac x 1 x 30 9587520 capsules cont as per	$50.0K	1
Voriconazole tablets 200MG 5 100 x 1 x 30 153 000 tablets Each film coated tablet contains voriconazole USP 200MG	$50.0K	1
Voriconazole tablets 200MG 5292pac x 1 x30 158760 tablets Each film coated tablet contains voriconazole USP 200MG	$50.0K	1
Tadalafil tablets USP 20MG 3918pac x 1 x500 1959000 tablets Each film coatedtablet contains tadalafil USP 20MG	$50.0K	1
Tadalafil tablets USP 5MG 106896pac x 1x 30 3206880 tablets Each film coatedtablet contains tadalafil USP 5MG	$50.0K	1
Duloxetine delayed release capsules 60MG 483216pacx1x30 14496480 capsules Each hard gelatin capsule cont as per	$50.0K	1

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Fenofibrate	Lipid & Metabolism	$1.3M	45	1.8%	11
2	Captopril	Cardiovascular	$1.2M	50	9.2%	2
3	Voriconazole	Advanced Antifungals	$850.0K	17	2.1%	4

Ajanta Pharma USA Inc. C/O Rxcrossr imports 3 pharmaceutical products across 3 categories into United States totaling $3.4M.

Ajanta Pharma USA Inc. C/O Rxcrossr — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Ajanta Pharma USA Inc., established in 2016, is a wholly owned subsidiary of Ajanta Pharma Limited, an Indian multinational pharmaceutical company founded in 1973. Headquartered in Bridgewater, New Jersey, Ajanta Pharma USA Inc. specializes in the development, manufacturing, and distribution of generic pharmaceutical products within the United States. The parent company, Ajanta Pharma Limited, operates globally, offering a diverse range of branded generic formulations across various therapeutic areas, including cardiology, dermatology, ophthalmology, and pain management.

In the U.S. market, Ajanta Pharma USA Inc. focuses on providing high-quality generic medicines, emphasizing both noncommunicable and infectious diseases. The company's product portfolio includes a mix of immediate-release, extended-release, delayed-release, orally disintegrating tablets, and powders. Ajanta Pharma USA Inc. is recognized for its commitment to quality, regulatory compliance, and supply chain excellence, ensuring reliable access to essential medications for patients across the United States.

2Distribution Network

Ajanta Pharma USA Inc. operates its distribution network from its headquarters in Bridgewater, New Jersey. While specific warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in New Jersey provides advantageous access to major transportation hubs, facilitating efficient distribution across the United States. This location enables the company to serve a broad geographic area, ensuring timely delivery of pharmaceutical products to meet market demands.

3Industry Role

In the United States pharmaceutical supply chain, Ajanta Pharma USA Inc. functions primarily as a pharmaceutical importer and distributor. By sourcing generic pharmaceutical formulations from its parent company, Ajanta Pharma Limited, and other suppliers, the subsidiary plays a crucial role in introducing cost-effective generic alternatives to the U.S. market. This strategy aligns with the industry's focus on expanding access to affordable medications, particularly in therapeutic areas with high unmet needs.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Ajanta Pharma USA Inc. C/O Rxcrossr

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Ajanta Pharma USA Inc. demonstrates a high degree of supplier concentration, with a significant portion of its imports originating from Ajanta Pharma Limited. This single-source dependency may present risks, such as potential supply chain disruptions or challenges in negotiating favorable terms. However, the consistent volume of shipments and the established relationship between the subsidiary and its parent company suggest a stable and reliable supply chain. The company's strategic focus on a select product portfolio may also mitigate risks associated with supplier concentration by reducing reliance on a broader range of suppliers.

2Supply Chain Resilience

Ajanta Pharma USA Inc.'s supply chain resilience is closely tied to the operations of Ajanta Pharma Limited. The parent company's manufacturing facilities in India, including those approved by the U.S. Food and Drug Administration (FDA), provide a foundation for the subsidiary's product offerings. While the company has not publicly disclosed information about backup suppliers or alternative sourcing strategies, the established relationship with Ajanta Pharma Limited and the focus on a select product portfolio suggest a degree of supply chain stability. However, the reliance on a single supplier may expose the subsidiary to risks associated with geopolitical events, regulatory changes, or operational challenges in the supplier's facilities.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the approval and monitoring of pharmaceutical products. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drugs, including generics, to ensure they meet safety, efficacy, and quality standards. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA), which provides the legal framework for drug approval and regulation. The Drug Approval Process involves submitting an Abbreviated New Drug Application (ANDA) for generics, demonstrating bioequivalence to the reference listed drug. Upon approval, the FDA issues a final approval letter, allowing the product to be marketed in the U.S.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the United States are governed by the FDA. Manufacturers and distributors must register with the FDA and comply with Good Manufacturing Practice (GMP) regulations to ensure product quality and safety. The FDA recognizes GMP certifications from various international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications facilitate the acceptance of foreign-manufactured drugs in the U.S. market, provided they meet the FDA's standards. Wholesale distribution authorization is also required, ensuring that entities involved in the distribution chain adhere to regulatory standards and maintain product integrity.

Ajanta Pharma USA Inc. C/O Rxcrossr — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Ajanta Pharma USA Inc.'s product strategy focuses on a selective approach, launching limited competition products in the U.S. market. This strategy allows the company to establish a meaningful presence in niche segments, particularly in therapeutic areas with high unmet needs. The company's portfolio includes products in cardiology, dermatology, ophthalmology, and pain management, aligning with its parent company's expertise. Market demand for these imports is driven by the need for affordable alternatives to branded medications, as well as the desire for high-quality generics in specialized therapeutic areas.

2Sourcing Profile

Ajanta Pharma USA Inc. primarily sources generic drug formulations from its parent company, Ajanta Pharma Limited. The focus is on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, rather than raw active pharmaceutical ingredients (APIs) or bulk drugs. This sourcing strategy leverages the parent company's manufacturing capabilities and established market presence, ensuring a reliable supply of high-quality generics. India's role in this procurement strategy is central, given its robust pharmaceutical manufacturing sector and compliance with international regulatory standards.

3Market Positioning

Seller's Guide — How to Become a Supplier to Ajanta Pharma USA Inc. C/O Rxcrossr

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Ajanta Pharma USA Inc., particularly in therapeutic areas where the company seeks to expand its portfolio. Gaps in Ajanta Pharma USA Inc.'s current sourcing may exist in products with limited competition or in emerging therapeutic segments. Indian exporters can explore these opportunities by offering products that align with the subsidiary's strategic focus and by demonstrating compliance with U.S. regulatory standards.

2Requirements & Qualifications

Indian exporters aiming to supply Ajanta Pharma USA Inc. and the U.S. market must obtain FDA approval for their products, which involves submitting an ANDA and complying with GMP regulations. Certifications such as EU GMP, WHO GMP, and PIC/S are recognized by the FDA and can facilitate market entry. Additionally, exporters must ensure that their products meet FDA labeling requirements, including providing information in English and adhering to serialization mandates.

3How to Approach

Frequently Asked Questions — Ajanta Pharma USA Inc. C/O Rxcrossr

What products does Ajanta Pharma USA Inc. C/O Rxcrossr import from India?

Ajanta Pharma USA Inc. C/O Rxcrossr imports 3 pharmaceutical products across 3 categories. Top imports: Fenofibrate ($1.3M), Captopril ($1.2M), Voriconazole ($850.0K).

Who supplies pharmaceuticals to Ajanta Pharma USA Inc. C/O Rxcrossr from India?

Ajanta Pharma USA Inc. C/O Rxcrossr sources from 1 verified Indian suppliers. The primary supplier is Ajanta Pharma Limited (100.0% of imports, $3.6M).

What is Ajanta Pharma USA Inc. C/O Rxcrossr's total pharmaceutical import value?

Ajanta Pharma USA Inc. C/O Rxcrossr's total pharmaceutical import value from India is $3.4M, based on 112 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Ajanta Pharma USA Inc. C/O Rxcrossr focus on?

Ajanta Pharma USA Inc. C/O Rxcrossr imports across 3 categories. The largest: Lipid & Metabolism (39.5%), Cardiovascular (35.6%), Advanced Antifungals (24.9%).

Get Full Ajanta Pharma USA Inc. C/O Rxcrossr Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.